Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Huang, Chao Yuan ^a   Huang, Shu Pin ^b,c   Lin, Victor C ^d,e   Yu, Chia Cheng ^f,g,h   Chang, Ta Yuan ⁱ   Lu, Te Ling ⁱ   Chiang, Hung Chih ⁱ   Bao, Bo Ying ^i,j,k  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d E DA HOSPITAL   (Taiwan)

^e I SHOU UNIVERSITY   (Taiwan)

^f KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

^h TAJEN UNIVERSITY   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY   (Taiwan)

^j CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^k ASIA UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATG16L1 PROTEIN, HUMAN; AUTOPHAGY RELATED PROTEIN; CARRIER PROTEIN; MAP1LC3B PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN;

AGED; AUTOPHAGY; CANCER STAGING; COHORT ANALYSIS; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIATION; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; AUTOPHAGY; AUTOPHAGY-RELATED PROTEINS; CARRIER PROTEINS; COHORT STUDIES; GENETIC VARIATION; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84941567091     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14045     Document Type: Article

References (25)

1. Draisma, G. et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95, 868-878 (2003).
2. Simmons, M. N., Stephenson, A. J. & Klein, E. A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 51, 1175-1184 (2007).
3. Akre, O. et al. Mortality among men with locally advanced prostate cancer managed with noncurative intent: A nationwide study in PCBaSe Sweden. Eur Urol 60, 554-563 (2011).
4. Walczak, J. R. & Carducci, M. A. Prostate cancer: A practical approach to current management of recurrent disease. Mayo Clin Proc 82, 243-249 (2007).
5. Ravikumar, B. et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 90, 1383-1435 (2010).
6. Mathew, R. & White, E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opin Genet Dev 21, 113-119 (2011).
7. Giatromanolaki, A., Sivridis, E., Mendrinos, S., Koutsopoulos, A. V. & Koukourakis, M. I. Autophagy proteins in prostate cancer: relation with anaerobic metabolism and Gleason score. Urol Oncol 32, 39 e11-38 (2014).
8. Huijbers, A. et al. The effect of the ATG16L1 Thr300Ala polymorphism on susceptibility and outcome of patients with epithelial cell-derived thyroid carcinoma. Endocr Relat Cancer 19, L15-18 (2012).
9. Nicoli, E. R. et al. Determination of autophagy gene ATG16L1 polymorphism in human colorectal cancer. Rom J Morphol Embryol 55, 57-62 (2014).
10. True, O. & Matthias, P. Interplay between histone deacetylases and autophagy-from cancer therapy to neurodegeneration. Immunol Cell Biol 90, 78-84 (2012).
11. Bao, B. Y. et al. Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clin Chim Acta 411, 1232-1237 (2010).
12. Huang, S. P. et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 18, 3068-3074 (2009).
13. Huang, S. P. et al. Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer. BJU Int 107, 486-492 (2011).
14. Yu, C. C. et al. Prognostic significance of cyclin D1 polymorphisms on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 20 Suppl 3, S492-499 (2013).
15. Freedland, S. J., Sutter, M. E., Dorey, F. & Aronson, W. J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61, 365-369 (2003).
16. Huang, S. P. et al. Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. Int J Cancer 135, 2661-2667 (2014).
17. Bao, B. Y. et al. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res 17, 928-936 (2011).
18. Ross, R. W. et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26, 842-847 (2008).
19. Genomes Project, C. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
20. Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100, 9440-9445 (2003).
21. Ward, L. D. & Kellis, M. HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40, D930-934 (2012).
22. Rosenbloom, K. R. et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res 41, D56-63 (2013).
23. Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. Nat Genet 45, 580-585 (2013).
24. Cerami, E. et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401-404 (2012).
25. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).